Diagnosing Coronary Heart Disease (CHD) with RCLS
Coronary Heart Disease (CHD) is an illness where plaque builds up inside the coronary arteries. The arteries play an important role in supplying oxygen-rich blood to the heart muscles, however, over time plaque builds up and can harden. This results in the arteries becoming narrow due to not being able to deliver enough oxygen-rich blood to the heart which causes angina or a heart attack to occur.1
BHF highlighted that Coronary Heart Disease was one of the UK’s biggest killers in 2010 resulting 46,000 premature deaths of which 68% were men.2
CHD is more likely with increasing age, particularly in men. These risk factors cannot be changed, however, there are other risk factors that can be modified such as blood cholesterol, being overweight or obese, smoking, lack of physical activity, unhealthy diet and stress.
You can prevent and control many CHD risk factors with heart-healthy changes and medication. Some lifestyles often increase the chance of developing the disease such as smoking, poor diet, adequate exercise therefore, there are many lifestyle changes to help control several CHD risk factors at the same time, such as physical activity which may reduce stress, lower your blood pressure, help control diabetes and help control your weight.3
Currently, there are four state of the art, fully functional ISO12025 accredited laboratories, located in Liverpool, London, Holywood and the Randox Science Park in Antrim giving RCLS the power to output to pharmaceutical, health and research markets.
Specialising in biomarker and multiplex testing in addition to standard safety and clinical testing, RCLS provides a full laboratory service to accelerate laboratory projects to completion. Our experienced project management teams are available to provide support and guidance from initial biomarker selection through to the design of a comprehensive results data package to deliver against your project aims and timelines.
Renowned for quality and reliability, the Rx Series and Evidence series are utilised by all RCLS Laboratories, guaranteeing real cost savings as well as highly-accurate flexible testing solutions. Furthermore, RCLS perform sample testing on numerous third-party analysers situated in our laboratories dependent upon the testing which is required by the customer.
RCLS can outsource the Cardiac Risk Prediction Array in their laboratory on the Evidence Investigator. We developed a rapid array which will allow all 19 SNPs to be genotyped simultaneously on one single sample. The RCLS team aim to save your laboratory time and money. By utilising our multiplex panels including the Cardiac Risk Prediction Array Panel, RCLS can offer labour saving, time reducing and cost-effective solutions for all your laboratory testing.
If you would like to find out more information about RCLS and what it has to offer contact email@example.com